INTRODUCTION
Rheumatoid arthritis (RA) belongs to the most prevalent chronic inflammatory autoimmune diseases, affecting joints, but also several other body organs, including the heart. The global prevalence of RA has been estimated at approximately 0.69% of the total population, with distinct environmental differences, as a greater incidence is...
observed among inhabitants of urban areas. Cachexia in RA (rheumatoid cachexia, RC), is mainly characterized by loss of muscle mass, in particular appendicular lean mass (ALM), and associated with accumulated fat mass (FM), situated mainly in the trunk area, indicating a shift towards the development of abdominal obesity. According to Rall and Roubenoff, loss of body cell mass (BCM) consists of an important issue of concern for patients with RA. BCM consists primarily of muscle and visceral mass (erythrocytes, serum proteins, lymphocytes, etc.), and is the part of the body with the greatest metabolic activity (95% of the total activity), determining protein requirements, energy expenditure, and the metabolic response to stress. In RA, patients lose between 13-15% of their BCM, an amount corresponding to 1/3 of the BCM volume that is associated with mortality. Thus, the increased mortality observed in patients with an RA diagnosis may be the product of altered body composition and subsequently, RC.

The prevalence of RC is high and it has been estimated that approximately 1/3 of the patients with an RA diagnosis develop cachexia. Body mass index (BMI) is not an appropriate tool for the detection of RC, as body fat (BF) may be within normal levels, or increased. Furthermore, different BMI cut-offs have been suggested for patients with RA, reduced by 2 kg/m² for each weight status tier, to better depict the changes in body composition due to RC. RC appears to be the result of several synergistic mechanisms, including an excessive production of inflammatory cytokines and hypermetabolism. Hypermetabolism in particular is the result of increased protein degradation and decreased muscle mass, which, in the presence of low physical activity levels and sedentary lifestyle, result to an increased accumulation of FM, further propelling inflammation. Moreover, the underlying testosterone deficiency and hypogonadism, paired with the observed decrease in the production of insulin and the intake of GC medication, pave the way for the development of RC.

The limited available studies on the effect of pharmacotherapy on RC suggest that the intake of corticosteroids (GC) and tumour necrosis factor α (TNF-α) inhibitors tend to increase FM accumulation, whereas the use of tocilizumab (TCZ) might induce a gain in lean body mass (LBM). These adverse changes in body composition are observed early on during the disease process. In rheumatology clinics, the assessment of body composition consists of a neglected issue, with most rheumatologists requiring further capacity building on the subject, or being too busy to screen patients. As a result, RC is often undiagnosed, unrecognized, and untreated. However, changes in body composition are not the only signs associated with RC, as underlying inflammation is actually propelling the development of RC, with pharmacotherapy acting in parallel and synergistically towards this goal, although the exact mechanisms have not yet been delineated. Patients with RC demonstrate increased pro-inflammatory cytokines, TNF-α and interleukin-1β (IL-1β) concentrations, further complicating the management of RA.

Lately, RC gained research interest with many studies being conducted, while providing evidence for its effective treatment. The aim of the present review was to synthetize all available scientific data to date regarding RC, its diagnosis, prevalence, associated factors and possible treatment modalities.
tinct publications), indicating a unit-of-analysis issue according to the Cochrane Collaboration. Moreover, several studies identified herein, were not included in the aforementioned meta-analysis, as the ones conducted by Hugo, Roubenoff, Santillán-Díaz, Müller, Pineda-Juárez, and the most recent ones published by Santo, Ångström and Papichev. The wide CI suggested by Santo and associates meta-analysis reflect the great heterogeneity of the pooled studies, the variety in disease progression observed in participants and the different methodology used to assess RC. Collectively, the available research indicates that studies of better quality are required to assess the prevalence of RC.

**Diagnostic criteria for RC**

Diagnostic criteria for RC differed greatly between studies (Table 2), with several researchers adopting the Engvall et al., criteria, some diagnosing RC using the Elkan et al., criteria and others tailoring their own criteria for RC diagnosis. According to Engvall, RC is diagnosed in patients with RA having a fat-free mass (FFM) below the 10th sex- and ethnic-specific percentile and a fat mass index (FMI) exceeding the 25th percentile. The Elkan criteria appear to be more liberal, diagnosing RC in every patient with RA exhibiting a FFM below the 25th percentile, in parallel to an FMI exceeding the 50th percentile. Ångström and associates compared the two diagnostic criteria and revealed a greater prevalence of RC when the Elkan criteria were applied. Müller and associates adopted their own criteria, diagnosing RC in patients with ALM/height<20th percentile for sex and ethnicity and BF (as a % of BW) >25% for men and >35% for women. Pineda-Juárez diagnosed RC in their sample using bioelectrical impedance vector analysis (BIVA). Van Bokhorst and associates applied the stricter staging system for general cachexia suggested by Evans et al. These incorporate BW loss (exceeding 5%) in the previous 12 months or less in the presence of underlying illness as the primary criterion, corroborated towards a diagnosis by three of the remaining criteria, namely a) low fat-free mass index (FFMI < 10th percentile), b) low muscle strength, c) fatigue, d) anorexia, and e) abnormal biochemistry regarding CRP, hemoglobin and IL-6 concentrations (Table 2). The researchers concluded that these criteria do not appear to be clinically useful for the identification and diagnosis of RC, mainly due to the low percentage of patients with RA exhibiting BW loss, although they may be of use for other patient groups with frequent cachexia. Consensus criteria for cachexia, defined as severe loss of BW, muscle and fat mass, were developed by the European Society for nutrition and metabolism (ESPEN), but none of the studies on RA patients have applied these criteria. Furthermore, cachexia is a distinct entity from RC, thus specific diagnostic criteria are required. Among the methods used to assess body composition in the identified primary studies, DXA was the most popular one, applied in 8 studies, followed by bio-electrical impedance analysis (BIA), DXA, and the Durnin and Womersley and Siri equations for the calculation of BF and body density, respectively. Elkan and associates additionally compared BIA to DXA and reported that the two methods appear to have a good relative agreement, however, the limits of agreement are wide, indicating that the use of BIA may be restricted for RC diagnosis in clinical practice.

**RC and sex**

According to Engvall, RC appears to affect predominantly women, however, the great majority (83%) of participants in his study were women. On the other hand, Table 1 indicates that women consist of the predominant sex in all of the primary studies, without necessarily demonstrating a greater prevalence of RC. It should be kept in mind that RA affects more women than men and that body composition changes during menopause, post-menopausal status is associated with greater loses in ALM and LBM, in general. According to the longitudinal Study of Women's Health Across the Nation (SWAN) cohort, the transition to menopause is associated with a double rate of BF accumulation, whereas the use of hormone replacement therapy (HRT) does not appear to predict changes in body composition independently. Overall, the transition to menopause and its distinct hormonal changes are considered as an important contributors to predisposing women to sarcopenia and osteoporosis, further aggravating the low physical activity levels. On the other hand, a recent meta-analysis suggested that the observed changes in the body composition of women are the result of ageing alone, with menopause possibly contributing only to the decrease in leg FM and the concomitant increase in central fat deposition. On the flip side, analysis of the University of California San Francisco (UCSF) cohort suggested that the LBM deficits observed in RA are greater among men, due to testosterone levels. In men, testosterone levels consist of an important regulator of muscle mass, and according to research, testosterone concentrations decrease in men with an RA diagnosis. Furthermore, improvements in disease activity have been shown to improve testosterone levels acutely, verifying the fact that inflammation suppresses testosterone production in this group. According to Cutolo and Straub, oestrogens act in both enhancing and inhibiting immune reactions, whereas androgens and progesterone exhibit anti-inflammatory and immunosuppressive effects and for this, RA has been...
suggested to be more severe in men compared to women. Moreover, the phenomenon of androgen-to-oestrogen conversion (intracrinology) is enhanced in inflamed tissues and RA in particular, indicating why androgen concentrations are frequently low, whereas on the other hand, oestrogens levels remain normal in patients with RA. These changes prompted researchers to propose androgens and progesterone as favourable therapeutic options in RA.

In conclusion, both sexes appear predisposed to altered body composition levels, either as a result of RA (men in particular), or the ageing process and some aspects of the menopause transition (women).

Disease activity and disease duration
Epidemiology
According to Fukuda, the continuation of inflammation appears to be essential for the decrease in muscle protein to occur in RC. Elevation of disease activity increases BMI through an increased deposit of FM, with a parallel decrease in visceral muscle being observed. As a result, research in Morocco revealed that greater disease activity and duration were associated with the prevalence of RC; whereas Engvall suggested that DAS28 correlated negatively with the LBM of patients. Utela further verified this, by showing that poorer muscle performance composite score (MPCS) was associated with greater disease activity in patients with RA. Further evidence was also provided early on by Roubenoff, who reported that LBM was associated with the number of swollen joints and a more recent study showing that disease activity was associated with changes in body composition, indicating the importance of aiming for remission when treating RA. On the other hand, the greatly heterogeneous pooled data by Santo failed to reveal the existence of a relationship between disease activity and duration with the prevalence of RC, in line with the results of Santillán-Díaz’s underpowered study. Thus, it is logical to assume that the lack of a relationship between disease activity and RC in these studies is probably the result of lower methodological quality.

Interventions
Since proinflammatory cytokines, and particularly TNF-α, are important inducers of RC, it is logical to expect that a reduction in inflammation (including TNF-α), would attenuate RC. However, a treat-to-target therapeutic approach with tight control in RA failed to attenuate RC. According to Lemmey, a possible explanation is that RC occurs early in the course of RA, probably even during the preclinical phase. This is indicated by the fact that muscle atrophy and decline in muscle strength are already present before the onset of pain and swelling in patients with RA. In the same vein, RC was associated with erythrocyte sedimentation rate (ESR) at the time of diagnosis and a similar degree of muscle depletion in patients with early RA, as well as in those with established RA. Nevertheless, BF appears to accumulate with disease duration, as a possible result of therapy.

Comorbidities associated with RC
Reported comorbidities associated with RC in relevant research include hypertension, excess in body weight (overweight and obesity), and it should be noted that RC does not appear to increase cardiovascular disease (CVD) risk. According to Masuko, the exact role of RC in increasing cardiovascular risk and clinical prognosis in RA is not clearly understood. However, when patients with RC and RA-free ones were compared, no differences were observed regarding classical or novel risk factors for cardiovascular disease (CVD), the prevalence of established CVD, or 10-year CVD mortality risk. According to Elkan, low physical activity levels in RA are associated with increased CVD risk, irrespective of body composition.

In an early case-control study of patients with RC, muscle density decline was associated with numerous inflammatory factors. RA disability was associated with adverse changes in body composition, with health assessment being inversely related to the ALM. However, RC and disability have only been evaluated by Roubenoff and associates, in the first recorded study evaluating the prevalence of RC. No other research has evaluated RC and disability together thus far. Despite the lack of research identifying comorbidities in RC, given that cachexia is a major factor for increased mortality risk, prompt interventions are required to prevent fatal metabolic abnormalities.

Rheumatic drugs, body composition and RC
Table 3 details all primary studies investigating changes in body composition parameters in patients with RA, following individual medication interventions, or combination therapeutic schemes. Methotrexate (MTX) monotherapy is the first line DMARD agent for DMARD-naive patients with RA. It is yet unknown if MTX monotherapy for RA is beneficial for RC. Santillán-Díaz and associates suggested that MTX administration with concomitant folic acid (FA) supplementation may protect against the development of RC. FA is a known cofactor in the metabolism of homocysteine, and low homocysteine levels are associated with greater muscle degradation, reduced muscle strength and lower physical function.

On the other hand, oral nutrient supplementation (ONS) with FA has been shown to reduce homocysteine concentrations during MTX therapy.

In a comparative effectiveness study, Marcora and associates compared the use of TNF blocking agents (etanercept, ETA) to MTX among patients with RA and showed that the latter induced a 14% increase in FFM
compared to a 44% increase observed in the ETA arm. Both therapies were effective in controlling disease activity and improving physical function. Chen and associates\(^76\) compared subcutaneous injections of ETA against non-biological DMARDs for 1 year and observed a greater BW gain, hyperuricemia prevalence, decreased fasting plasma glucose-dependent insulinotropic polypeptide (GIP) concentrations, and loss of post-oral glucose suppression of plasma leptin concentration in the ETA arm. In a similar trial, Engvall\(^77\) compared treatment with a combination of DMARDs against MTX plus anti-TNF (infliximab, IFX) for a total of 2 years. IFX therapy induced an increment in BF mass, whereas a similar effect was not achieved with the DMARDs combination, despite the fact that both treatments resulted in akin reductions in disease activity. This indicated that the accumulation of FM appears to be drug-specific. In a small sample of women with an RA diagnosis, Serelis\(^78\) evaluated the effect of IFX compared to adalimumab (ADA), on the body composition and adiponectin levels of participants. One year of intervention failed to induce any changes in LBM and FM and no differences were noted in the lumbar spine BMD of participants. On the other hand, anti-TNF treatment for 1-year increased serum adiponectin concentrations significantly. In a similar trial, Toussirot\(^79\) administered three different anti-TNF agents (IFX, ETA, or ADA) to patients with RA and ankylosing spondylitis (AS). After two years of follow-up, a gain in BMI was recorded and an increase in visceral and android fat among patients with RA. Collectively these trials suggest that anti-TNF agents are not effective in increasing muscle mass and are associated with greater FM as compared to csDMARD alone, in particular regarding fat accumulated in the trunk.\(^24,65\)

However, an epidemiological analysis of the Veterans Affairs RA (VARA) registry\(^80\) revealed that MTX was associated with a reduced risk of BW loss, whereas prednisone or anti-TNF therapies were not associated with changes in the BMI or the risk of BW loss, independent of other factors. According to Santillan-Diaz,\(^22\) this MTX-induced positive metabolic balance can explain its effects on the immune response effects, namely the extracellular increase in adenosine, and the inhibition of the transcription factor NFκB, the endothelial and inflammatory cell function, the T-cell function regulation.\(^81,82\)

Prednisolone, is a GC, reducing inflammation and improving physical function rapidly and effectively, thus, frequently used as a first-line treatment in RA as part of a combination therapy with other DMARDs. Konijn et al.\(^83\) investigated the effect of two different prednisolone doses, a high-dose and a step-down regimen on the body composition of patients with early RA. Both prednisolone regimens increased total body mass, through an accumulation of FM. However, fat redistribution from peripheral to central tissues was not recorded, contradicting the previous assumption of rapid adverse effects of prednisolone on the body composition of patients with RA. On the other hand, Lin et al.\(^33\) revealed that when patients with a normal BMI were considered, approximately 18.2% exhibited myopenia overlapping with overfat. Moreover, in this normoweight subgroup of patients with RC, the worst radiographic scores and highest rates of previous GC treatment and hypertension diagnosis were also exhibited.\(^33\) Compared to the patients not exhibiting myopenia and overfat, the normoweight ones with RA on previous GC treatment exhibited a higher rate of myopenia, overlapping with overfat.\(^33\) In concert to this observation, Hugo and associates\(^84\) noted that low levels of physical activity and treatment with GCS was associated with increased nutritional complications among patients with RA, including RC and metabolic syndrome. A more recent study conducted in Russia\(^85\) suggested that the median cumulative dose of oral GC in patients with RC appears to be higher, although the finding was not statistically significant. Nevertheless, an early study\(^86\) also reported a greater steroid cumulative dose among patients with RC, indicating that changes in body composition are also therapy-driven.

Apart from TNF-α blockers, other anti-inflammatory agents are often employed in the management of RA. Tournadre and associates\(^83\) evaluated the effect of TCZ treatment, a humanized anti-IL-6 receptor monoclonal antibody, on the body composition and metabolic profile of patients with RA. After one year of treatment with TCZ, BW was significantly increased without any observed changes in the FM. Between months 6-12 of treatment, an increase in appendicular lean mass and skeletal muscle mass index was observed, with a redistribution of BF. The trunk/peripheral fat ratio was decreased and subcutaneous adipose tissue was increased. No changes were noted regarding blood pressure, waist circumference, fasting glucose concentrations, or the atherogenic index of participants. These findings were also confirmed by a French multicentric study, the évolution des ADIpokines et de la composition corporelle chez les patients atteints de Polyarthrite Rhumatoïde et recevant un traitement par Tocilizumab (ADIPRAT) phase IV open-label clinical trial.\(^84\) In the ADIPRAT,\(^84\) patients with RA were administered intravenous TCZ (8 mg/kg monthly), as administered in daily practice, with the option to decrease TCZ dosage to 4 mg/kg at the rheumatologist's discretion and the possibility to reduce GCS intake whenever deemed required. After one year of intervention, an increase in adiponectin concentrations was noted, especially at the onset of the treatment. Furthermore, TCZ induced significant gain in LM, BMI and waist circumference, while FM remained unchanged. Schultz and associates\(^85\) evaluated the administration of TCZ in 11 patients with rheumatic diseases (no further information was provided), who were diabetes-free. TCZ treatment for 3 months
significantly decreased the homeostatic model for insulin resistance (HOMA-IR), and increased serum adiponectin concentrations. Serum triglycerides, LDL and HDL tended to be increased, whereas lipoprotein (a) levels were lowered post-treatment.85 Finally, Fioravanti86 evaluated TCZ administration (8 mg/kg TCZ IV, once every 4 weeks) as monotherapy, or on top of MTX treatment for a total 6 months. ESR, CRP, DAS28-ESR and health assessment questionnaire (HAQ) were improved in both arms. In parallel, total cholesterol concentrations were increased and chemerin was decreased in both arms. Furthermore, a variety of methodological issues are apparent in research. Overall, it is difficult to define the exact effect medications have on RC, as most of the studies are either comparing different medication regimens, as it is unethical to leave the patients without medication. Moreover, several trials83-85 used control arms comprising of patients not receiving any medication, whereas one trial used healthy controls as comparators86-87. With regard to the participants included in the aforementioned research items, the majority of studies used patients with RA, medication-naïve or on medication, with active or inactive RA, where changes in body composition were recorded during the course of intervention. Only the trial conducted by Schultz85 used patients with RC as the patient pool for their intervention.

**Dietary treatments, body composition and RC**

Observational data from the National Health and Nutrition Examination Survey (NHANES) and several smaller studies indicate that patients with RA tend to follow diets of low or suboptimal quality.87-90 Medical nutrition therapy (MNT) in RA mainly aims in stimulating an overexpression of anti-inflammatory cytokines and controlling RC, with tailored nutrition interventions focusing on overcoming impaired protein synthesis and reverting muscle catabolism. A total of four intervention studies have evaluated the use of ONS in body composition among patients with RA, using an RCT design (Table 4). Wilkinson94 administered ONS against placebo as an add-on therapy for 12 weeks and revealed that although supplementation with creatine increased total and appendicular LM, it failed to improve isometric knee extensor and handgrip strength, and physical function. Marcora and associates95 compared the results of two different amino-acid drinks administered for 12 weeks, one containing 3 g beta-hydroxy-beta-methylbutyrate (HMB, calcium salt), 14 g of L-arginine (ARG) and 14 g L-glutamine (GLN), diluted in 240 mL of water, drank twice/daily and a comparator drinks with a nitrogen (7.19 g/day) and calorie (180 kcal/day) balanced mixture of ARG (11 g), GLN (1.75 g), L-glycine (6.10 g) and L-serine (4.22 g), diluted in 240 mL of water, drank twice/daily. Dietary supplementation with HMB/GLN/ARG was not superior to placebo in the treatment of RC. However, both amino acid mixtures increased FFM, total body protein (TBP), arms and legs LM, and some measures of physical function. Aryaeian et al.96 hypothesised that ONS with barberry extract might improve anthropometry and glycemia in patients with RA. Using a placebo-controlled design, they demonstrated that after 3 months BW, BMI, and concinity index increased similarly in both groups. On the other hand, BF (%), low-density lipoprotein (LDL), hips circumference, fasting plasma glucose (FPG), and systolic blood pressure were all decreased in the intervention arm compared to the placebo. Lovell97 evaluated supplemental Calcium (Ca) intake on the bone mineral density (BMD) of patients with juvenile RA. The two treatment arms received 1,000 mg of Ca and 400 IU of vitamin D, or vitamin D alone, for a duration of two years. At 24 months, the mean BMD among the youngsters receiving Ca was greater, independently of sex, Tanner’s puberty stage, medication adherence, or other factors. Finally, recent research on animals indicated that ONS with coriander98 might have favorable effects in restoring muscle mass, however, this finding has not been verified on humans. In summary, with regard to the dietary supplements, amino acids appear to be promising in improving body composition and possibly attenuating RC although more research is required to validate the findings. Antioxidant supplements like barberry extract appear to target glycemia and by inference, an improvement in other metabolic factors, including anthropometry, may be noted.

**Metabolism, body composition and RC**

According to Spies,99 in RA, energy metabolism is regulated by chronic inflammation, not only with regard to energy supply, but additionally for immune response activation and control, through a variety of metabolic signals.100,101 Thus, the existence of chronic, low-grade inflammation diverts energy and glucose metabolism from other systems in order to support the requirements for immune response activation.102,103 In the presence of a chronic pro-inflammatory environment, macrophages and lymphocytes switch from a resting state to a highly active one, pedaling the release of host-defense factors promoting phagocytosis and antigen production.104 To counterbalance this metabolic shift, lipid and protein catabolism increase for the production of ATP.105 The higher inflammatory cytokine production stimulates muscle catabolism through the nuclear-factor κB (NF-κB)-dependent pathway,106 increasing the whole-body protein turnover, triggering muscle loss and the development of cachexia.106 This net protein shortage further increases metabolic rate and in particular, resting energy expenditure (REE) in patients with RA.12,13,24,107 However, total energy expenditure (TEE) levels appear lower compared to the rest of the population, mainly as a result of low physical activity levels.108
TEE consists of the sum of the thermic effect of food (TEF), REE and physical-activity energy expenditure (PAEE). With the TEF being dependent on the amount of consumed food, and TEE in RA appears to be mostly influenced by the REE and PAEE of patients. In this manner, the increased REE and the reduced PAEE are developing an energy deficiency environment, further driving the cachectic state.\textsuperscript{109} Several lines of evidence suggest that REE, disease activity and severity are inter-related in RA and RC. In all of these studies, REE was measured using indirect calorimetry.\textsuperscript{107,110,111} When REE is calculated using prediction equations instead of being measured, it is not associated with any score or biomarker of disease activity.\textsuperscript{112} On the other hand, RA-specific equations for the calculation of REE have been proposed, taking into account the levels of CRP.\textsuperscript{113}

In the same vein, although malnutrition would be the logical sequence in this inflammatory environment, the use of standard malnutrition assessment tools seems to fail to detect the need for nutrition intervention in RA, as there may be an increase in FM.\textsuperscript{45,86,111} This results in masking the identification of patients in higher risk for RC, since the assessment of cachexia is rarely performed in clinical practice.

\textit{Limitations of existing research}

A major limitation in the available research on RC involves the diagnostic criteria applied. RA sensitive criteria are necessary for RC diagnosis although it appears that the use of different criteria, not specific to RA increase bias and do not allow for generalization or pooling of the primary studies. Thus, it appears that the need for conducting studies of better quality aiming to assess the prevalence of RC is apparent.

\textbf{CONCLUSIONS}

In 1873, Sir James Paget\textsuperscript{115} first described RC; however, research on effective interventions to manage this important problem remains in infancy. It appears that the complex pathophysiology of RA, the adverse effects of polypharmacy in body composition, and the deteriorating metabolic alterations, develop a complex situation which becomes difficult to balance. Nonetheless, it appears that triage for RC identification should be performed as early as RA diagnosis, with constant monitoring of the condition thereafter, in order to better understand the mechanistic effects of RC and improve prognosis in affected patients.

\textbf{CONFLICT OF INTEREST}

The authors declare no conflict of interest.

\textbf{REFERENCES}


to rheumatoid cachexia. Mod Rheumatol 2010;20:439-43.


Table 1. Primary studies assessing RC in patients with RA.

<table>
<thead>
<tr>
<th>First author</th>
<th>Study</th>
<th>Participants</th>
<th>RA Diagnostic criteria</th>
<th>Body composition method</th>
<th>RC Diagnostic criteria</th>
<th>Prevalence (%)</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hugo et al.</td>
<td>France</td>
<td>CC 2010–4</td>
<td>Bordeaux University Hospital</td>
<td>N (% women)</td>
<td>NR</td>
<td>ACR</td>
<td>DxA</td>
</tr>
<tr>
<td>Lombard et al.</td>
<td>S. Africa</td>
<td>CS NR</td>
<td>Tygerberg Hospital and Groote Schuur Hospital</td>
<td>251 (83%) patients with RA</td>
<td>NR</td>
<td>Skinfolds (Durnin and Womersley) and the Siri equations</td>
<td>12</td>
</tr>
<tr>
<td>Van Bokhorst et al.</td>
<td>The Netherlands</td>
<td>CS 2011</td>
<td>Department of Rheumatology at the VU Medical Center</td>
<td>103 (79%) consecutive patients with RA</td>
<td>NR</td>
<td>BIA</td>
<td>Evans et al.</td>
</tr>
<tr>
<td>Santillán-Díaz</td>
<td>Mexico</td>
<td>CC NR</td>
<td>Rheumatology Clinic at the Instituto Nacional de Rehabilitación</td>
<td>94 (92.55%) patients with RA, 20 as cases (with RC) and 74 as RC-free patients</td>
<td>NR</td>
<td>ACR/ EULAR115</td>
<td>BA (Systems Quantum X, Clinton Twp, MI, USA) a vector analysis method (BVA Software 2002) NOD</td>
</tr>
<tr>
<td>Metsios et al.</td>
<td>UK</td>
<td>CC NR</td>
<td>Department of Rheumatology of the Dudley Group of Hospitals</td>
<td>34 patients with RA and RC and 366 patients with RA (RC-free), all from the PRACCO cohort (73%)</td>
<td>NR</td>
<td>BIA (Tanita BC418MA, Tokyo, Japan)</td>
<td>Engvall et al.</td>
</tr>
</tbody>
</table>

Continued on next page
### Table 1. Primary studies assessing RC in patients with RA.

<table>
<thead>
<tr>
<th>First author</th>
<th>Study</th>
<th>Participants</th>
<th>RA Diagnostic criteria</th>
<th>Body composition method</th>
<th>RC</th>
<th>Prevalence (%)</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maghraoui36</td>
<td>Morocco CS June–December 2013 Military Hospital of Rabat</td>
<td>178 patients with RA (82.6%)</td>
<td>NR</td>
<td>54.1±11.5</td>
<td>ACR</td>
<td>DXA (Lunar Prodigy)</td>
<td>Engvall et al.18</td>
</tr>
<tr>
<td>Elkan45 and</td>
<td>Sweden CS NR Rheumatology Department, Karolinska University Hospital Huddinge</td>
<td>80 consecutive outpatients with RA (76%)</td>
<td>NR</td>
<td>61±</td>
<td>NR</td>
<td>DXA (GE-Lunar Prodigy) and BIA (Tanita Corp., Tokyo, Japan)</td>
<td>Engvall et al.18</td>
</tr>
<tr>
<td>Engvall18</td>
<td>Sweden CS NR Karolinska University Hospital</td>
<td>60 patients with RA (83%)</td>
<td>NR</td>
<td>66±</td>
<td>ACR</td>
<td>DXA (GE-Lunar Prodigy)</td>
<td>Engvall et al.18</td>
</tr>
<tr>
<td>Papichev37</td>
<td>Russia CS NR</td>
<td>NR</td>
<td>110 patients with RA (NR%)</td>
<td>NR</td>
<td>52.2±8.1</td>
<td>ACR/ EULAR</td>
<td>DXA</td>
</tr>
<tr>
<td>Ångström38</td>
<td>Sweden CS 2013-6 Department of Rheumatology, University Hospital of Umeå</td>
<td>87 patients with early RA (NR%)</td>
<td>71.3</td>
<td>60±</td>
<td>ACR/ EULAR</td>
<td>DXA (GE-Lunar Prodigy)</td>
<td>Engvall et al.18 and Elkan44</td>
</tr>
<tr>
<td>First author</td>
<td>Study Design</td>
<td>Duration</td>
<td>Recruitment Site</td>
<td>N (% women)</td>
<td>RR (%)</td>
<td>Age (years)</td>
<td>RA Diagnostic Criteria</td>
</tr>
<tr>
<td>-----------------------</td>
<td>--------------</td>
<td>----------</td>
<td>-----------------</td>
<td>-------------</td>
<td>--------</td>
<td>-------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>Roubenoff<strong>21</strong></td>
<td>USA CS</td>
<td>1</td>
<td></td>
<td>24 patients with RA</td>
<td>1</td>
<td>1</td>
<td>BIA</td>
</tr>
<tr>
<td>Pineda-Juárez*39</td>
<td>Mexico CS</td>
<td>2015–6</td>
<td>Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán and Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra</td>
<td>224 women with a diagnosis of RA (100%)</td>
<td>NR 52.7±14.2</td>
<td>MS 14.2 <strong>2</strong></td>
<td>ACR/EULAR</td>
</tr>
<tr>
<td>Müller*40**</td>
<td>Estonia CC</td>
<td>2012–4</td>
<td>Patients: NR Controls: Postal invitations</td>
<td>91 patients with early RA (72%) and 328 healthy controls (54%)</td>
<td>NR 19–79</td>
<td>ACR/EULAR</td>
<td>DXA (Lunar Prodigy Advance)</td>
</tr>
<tr>
<td>Murillo-Saich*42</td>
<td>Mexico CC</td>
<td>NR NR</td>
<td>NR NR</td>
<td>84 women with RA and 127 healthy women as controls (100%)</td>
<td>NR 24–89</td>
<td>ACR</td>
<td>DXA (Lunar Prodigy Advance)</td>
</tr>
</tbody>
</table>
Table 1. Primary studies assessing RC in patients with RA. Continued from previous page

<table>
<thead>
<tr>
<th>First author</th>
<th>Study</th>
<th>Participants</th>
<th>RA Diagnostic criteria</th>
<th>Body composition method</th>
<th>RC Diagnostic criteria</th>
<th>Prevalence (%)</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Santo47</td>
<td>Brazil Prospective cohort (1 year)</td>
<td>Hospital de Clínicas de Porto Alegre, HCPA</td>
<td>90 patients with RA (88.9%)</td>
<td>90</td>
<td>56.5±7.3(MSD)</td>
<td>ACR/EULAR DXA (GE-Lunar Prodigy Primo)</td>
<td>Engvall et al. 18</td>
</tr>
</tbody>
</table>

ACR: American College of Rheumatology; ALM: appendicular lean mass (the sum of the lean tissue in the arms and legs); anti-PC: antibodies against phosphorylcholine; BF: body fat; BIA: bioelectrical impedance analysis; BIVA: Bioelectrical impedance vector analysis; BMD: bone mineral density; BMI: body mass index; CC: case-control; CRP: C-reactive protein; CS: cross-sectional; DAS28: disease activity score (28 joints); DMARD: disease-modifying antirheumatic drug; DRACCO: Dudley RA comorbidity cohort; DXA: dual-energy X-Ray absorptiometry; ESR: erythrocyte sedimentation rate; EULAR: European Alliance of Associations for Rheumatology; FFM: fat-free mass; FM: fat mass; GC: glucocorticoid; IL-6: interleukine 6; LBM: lean body mass; LDL: low-density lipoprotein; M: median; MS: metabolic syndrome; MSD: mean ± standard deviation; NOD: nod other defined; NR: not reported; PA: physical activity; PC: percentile; R: range; RA: rheumatoid arthritis; RC: rheumatoid cachexia; RR: response rate; SFA: saturated fatty acids; VF: vertebral fractures; * no difference was noted in the prevalence of RC between baseline and the end of the study (at 1 year); † access to the full-text of the publication was not possible, thus, only available data from the abstract are presented.
<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>BW loss</th>
<th>FFMI (kg/m²)</th>
<th>FMI (kg/m²)</th>
<th>BF (% of BW)</th>
<th>Low muscle strength</th>
<th>Fatigue</th>
<th>Anorexia</th>
<th>Abnormal biochemistry</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rheumatoid cachexia</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Engvall et al.</td>
<td></td>
<td>&lt;10th PC’</td>
<td>&gt;25th PC’</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elkan et al.44</td>
<td></td>
<td>&lt;25th PC’</td>
<td>&gt;50th PC’</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Müller40</td>
<td>ALM/height²</td>
<td>&lt;20th PC’</td>
<td></td>
<td>&gt;25% for men, &gt;35% for women</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cachexia</td>
<td>≥5% in the previous 12 months, or less in the presence of illness, or BMI &lt;20 kg/m², plus 3/5 of the other criteria (on the right columns)</td>
<td>&lt;10th PC’, or ASMI (by DXA) &lt;7.25 in men and &lt;5.45 in women</td>
<td>+ (assessed via handgrip strength)</td>
<td>+</td>
<td>Limited food intake (i.e. EI&lt;20 kcal/kg of BW/day, or &lt;70% of usual food intake), or poor appetite</td>
<td>+</td>
<td>Elevated inflammatory markers (CRP&gt;5.0 mg/L, or IL-6 &gt;4.0 pg/mL)</td>
<td>+</td>
</tr>
</tbody>
</table>

ALM: appendicular lean mass (the sum of the lean tissue in the arms and legs: calculated by DXA); ASMI: appendicle skeletal muscle index; BMI: body mass index; BF: body fat; BW: body weight; CRP: c-reactive protein; DXA: dual-energy x-ray absorptiometry; EI: energy intake; Hb: haemoglobin; FMI: fat mass index; FFMI: fat-free mass index; IL-6: interleukin 6; PC: percentile; ° of the sex-, age-, and ethnic-specific values; †: oedema free. Background colours denote the component criteria used in each definition.
Table 3. Primary studies evaluating the effects of medication for RA on body composition and cachexia.

<table>
<thead>
<tr>
<th>First author</th>
<th>Design</th>
<th>Participants</th>
<th>Intervention(s)</th>
<th>Comparator(s)</th>
<th>duration</th>
<th>Outcomes</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marcora⁶５</td>
<td>Parallel RCT</td>
<td>N=26 patients with early RA</td>
<td>ETA (vials reconstituted with bacteriostatic water, injected subcutaneously twice/week) (n=12)</td>
<td>MTX per os (7.5 mg/week for a month, increased to a maximum of 15 mg/week for the 2nd month and 20 mg/week for the subsequent 4th month if deemed necessary) (n=12)</td>
<td>24 weeks</td>
<td>Body composition, physical function, disease activity, systemic inflammation, IGF levels</td>
<td>Approximately 44% of BW gained in the etanercept group was FFM, as compared to only 14% in the MTX arm.</td>
</tr>
</tbody>
</table>

| Tournadre⁸³ | CC | N=21 patients with active RA and 21 RA-free matched controls | TCZ (n=21) | No treatment (n=21) | 1 year | WC, BMI, BP, lipid profile, FPG, insulin, serum levels of adipokines and pancreatic/gastrointestinal hormones, and body composition (DXA) | Compared with controls, body composition was altered in RA with a decrease in total and appendicular LM, without any changes in BF. Among patients with RA, 28.6% had a skeletal muscle mass index below the cut-off for sarcopenia (4.8% of controls). After 1 year of treatment, a gain in BW was noted, without any changes in FM. An increase in LM was observed with a significant gain in appendicular LM and skeletal muscle mass index between 6–12 months of treatment. FM was decreased in the trunk/peripheral fat ratio, and increased in the subcutaneous adipose tissue. No changes were noted for WC, BP, FPG or atherogenic index. |

Continued on next page
Table 3. Primary studies evaluating the effects of medication for RA on body composition and cachexia.

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>N</th>
<th>Intervention</th>
<th>Duration</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schultz\cite{287}</td>
<td>CT N=11 non-diabetic patients with RD</td>
<td>TCZ (NOD) (n=11)</td>
<td>None</td>
<td>3 months</td>
<td>HOMA-IR, serum levels for leptin, adiponectin, TG, LDL, HDL and Lp(a)</td>
</tr>
<tr>
<td>Toussrot\cite{287}</td>
<td>Open label CT N=77 patients with active RA</td>
<td>TCZ IV 8mg/kg monthly, as administered in daily practice, with the option to decrease TCZ dosage to 4 mg/kg at the rheumatologist’s discretion (n=77)</td>
<td>None</td>
<td>1 year</td>
<td>BMI and anthropometry, lipid and metabolic parameters, serum adiponectin, leptin, resistin, ghrelin, body composition (DXA)</td>
</tr>
<tr>
<td>Fioravanti\cite{287}</td>
<td>CT N=44 patients with active RA</td>
<td>IV TCZ (8 mg/kg) once every 4 weeks (n=20)</td>
<td>IV TCZ (8 mg/kg) once every 4 weeks, plus MTX (n=24)</td>
<td>6 months</td>
<td>BMI, DAS28, HAQ ESR, CRP, DAS28-ESR and HAQ improved in both arms. TC was increased and chemerin was decreased in both arms.</td>
</tr>
<tr>
<td>Chen\cite{287}</td>
<td>Non-randomized CT N=30 patients with RA</td>
<td>Subcutaneous injections of ETA twice weekly (n=20)</td>
<td>Non-biological DMARDs (n=10)</td>
<td>12 months</td>
<td>BW, BF, appetite rating, lipid profiles, gut hormones and leptin</td>
</tr>
</tbody>
</table>

The HOMA-IR decreased significantly, leptin concentrations were not altered but adiponectin levels increased. Serum TG, LDL and HDL tended to be increased, whereas Lp(a) levels was lowered. TCZ treatment was associated with an increase in adiponectin, especially at the onset of the treatment and induced a significant gain in LM, BMI and WC, while FM did not change. In addition, TCZ may have an anabolic impact on lean mass/skeletal muscle. ETA induced significant BW gain, hyperuricemia, decreased fasting plasma GIP levels, and loss of post-oral glucose suppression of plasma leptin concentration. Appetite score and serum lipid profiles did not change.
<table>
<thead>
<tr>
<th>Study</th>
<th>Type</th>
<th>Patients Details</th>
<th>Treatment Details</th>
<th>Follow-up</th>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Toussirot79</td>
<td>Parallel CT</td>
<td>N=8 patients with RA non-responders to DMARDs and 12 with AS</td>
<td>IFX (3 or 5 mg/kg in RA and AS, respectively) (n=7)</td>
<td>2 years</td>
<td>DXA, HAQ, ESR, CRP, DAS28, serum leptin, adiponectin, resistin, and ghrelin levels, body composition (DXA)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ETA (50 mg/weekly) (n=7)</td>
<td></td>
<td>A gain in BMI and a tendency for BW gain, android and visceral fat increase was noted in patients with RA.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ADA (40 mg every other week) (n=12)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serelis78</td>
<td>Parallel CT</td>
<td>N=19 women with active RA</td>
<td>IFX (3 mg/kg) at weeks 0, 2, 6 and thereafter systematically every 8 weeks</td>
<td>1 year</td>
<td>BMI, body composition (DXA), adiponectin</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(n=10)</td>
<td></td>
<td>No change in LBM, or FM and no difference was noted in lumbar spine BMD. Serum concentrations of adiponectin increased after 1 year of anti-TNF treatment.</td>
</tr>
<tr>
<td>Engvall77</td>
<td>Parallel RCT</td>
<td>N=40 patients with early RA who failed MTX treatment (20 mg/week for 3 months)</td>
<td>MTX (20 mg/week) plus SSZ and hydroxychloroquine (n=22)</td>
<td>21 months</td>
<td>Body composition (DXA), BMD, leptin, adiponectin, apo-lipoproteins, IGF-1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>MTX treatment (20 mg/week) plus IFX (n=18)</td>
<td></td>
<td>Patients treated with anti-TNF had a significant increase in fat mass compared to the other arm, despite similar reduction in disease activity. Both treatments prevented loss of muscle mass and bone. Leptin concentrations increased in both arms. No changes were recorded for apolipoproteins or IGF-1. The markers of bone resorption decreased at 12 months in both arms, without difference between them.</td>
</tr>
</tbody>
</table>

**Table 3.** Primary studies evaluating the effects of medication for RA on body composition and cachexia. **Continued from previous page**
Table 3. Primary studies evaluating the effects of medication for RA on body composition and cachexia.

<table>
<thead>
<tr>
<th>Study</th>
<th>Design</th>
<th>Group</th>
<th>Medication Details</th>
<th>Time</th>
<th>Body Composition (DXA)</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Konijn</td>
<td>Parallel RCT</td>
<td>N=108 prednisolone-naive patients with recent-onset RA</td>
<td>COBRA (prednisolone 60 mg/day, tapered to 7.5 mg/day in 6 weeks; MTX and SSZ) (n=54)</td>
<td>26 weeks</td>
<td></td>
<td>There were no differences between the treatment groups. BW and FM were increased. The trunk/peripheral fat ratio and the proportional distribution of BW and FM remained stable over time.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>COBRA-light therapy (PSL 30 mg/day, tapered to 7.5 mg/day in 8 weeks, plus MTX) (n=54)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metsios</td>
<td>CC</td>
<td>N=20 patients with RA and N=12 healthy controls</td>
<td>anti-TNF treatment (n=20)</td>
<td>No treatment (n=12)</td>
<td>12 weeks</td>
<td>BIA (Tanita BC-418-MA), TNF-α, physical activity, REE, DAS28</td>
</tr>
</tbody>
</table>

ADA: adalimumab; AS: ankylosing spondylitis; BF: body fat; BIS: bioelectrical impedance spectroscopy; BMD: bone mineral density; BMI: body mass index; BP: blood pressure; BW: body weight; CC: case-control; COBRA: Combinatietherapie bij Reumatoide Artritis; CT: clinical trial; DAS28: disease activity score (28 joints); DMARD: disease-modifying antirheumatic drug; DXA: dual x-ray absorptiometry; ESR: erythrocyte sedimentation rate; ETA: etanercept; FFM: fat-free mass; FM: fat mass; FPG: fasting plasma glucose; GIP: glucose-dependent insulinotropic polypeptide; HAQ: health assessment questionnaire; HDL: high-density lipoprotein; HOMA-IR: homeostatic model for insulin resistance; IFX: infliximab; IGF: insulin-like growth factor; IV: intravenous; LDL: low-density lipoprotein; LM: lean mass; Lp(a): lipoprotein (a); MTX: methotrexate; NOD: not other defined; PSL: prednisolone; RA: rheumatoid arthritis; RCT: randomized controlled trial; RD: rheumatic diseases; REE: resting energy expenditure; SSZ: sulfasalazine; TBP: total body protein; TC: total cholesterol; TCZ: tocilizumab; TG: triglycerides; TNF: tumor necrosis factor; WC: waist circumference.
Table 4. RCTs evaluating effects of oral nutrient supplementation on body composition and cachexia among patients with RA.

<table>
<thead>
<tr>
<th>First author</th>
<th>Design</th>
<th>Participants</th>
<th>Intervention(s)</th>
<th>Comparator(s)</th>
<th>duration</th>
<th>Outcomes</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wilkinson94</td>
<td>Parallel RCT</td>
<td>N=40 patients with RA</td>
<td>Creatine ONS [20 g of Cr monohydrate (MyProtein), 4×5 g/day for the initial 5 days (loading dose) followed by 3 g/day for the remainder of the 12-week period (maintenance dose)], mixed with a mango-flavoured drink powder (Foster Clark Products) to improve taste (n=15)</td>
<td>Placebo ONS (flavoured drink powder) (n=20)</td>
<td>12 weeks</td>
<td>Body composition (DXA and BIS), strength, aerobic capacity (Vo2max) and physical function</td>
<td>ONS with creatine increased total and appendicular LM, but failed to improve isometric knee extensor and handgrip strength, or objectively assessed physical function.</td>
</tr>
<tr>
<td>Marcora95</td>
<td>Parallel RCT</td>
<td>N=40 patients with RA</td>
<td>ONS with 3 g HMB (calcium salt), 14 g ARG and 14 g GLN, diluted in 240 mL of water, drank twice/daily (n=20)</td>
<td>ONS with placebo (nitrogen (7.19 g/day) and calorie (180 kcal/day) balanced mixture of ARG (11 g), GLN (1.75 g), L-glycine (6.10 g) and L-serine (4.22 g), diluted in 240 mL of water, drank twice/daily (n=20)</td>
<td>12 weeks</td>
<td>Body composition and physical function</td>
<td>Dietary ONS with HMB/GLN/ARG was not superior to placebo in the treatment of RC. Both amino acid mixtures increased FFM, TBP, arms and legs LM, and some measures of physical function.</td>
</tr>
<tr>
<td>Lovell97</td>
<td>Parallel RCT</td>
<td>N=198 children and adolescents with juvenile RA</td>
<td>ONS with 1,000 mg of Ca and 400 IU of vitamin D (n=103)</td>
<td>ONS with matched placebo tablets and 400 IU of vitamin D (n=95)</td>
<td>24 months</td>
<td>BMD (DXA)</td>
<td>At 24 months, the mean BMD among those receiving Ca was greater, independently of sex, Tanner stage, adherence to medication, etc.</td>
</tr>
<tr>
<td>Aryaeian96</td>
<td>Parallel RCT</td>
<td>N=62 patients with active RA</td>
<td>ONS with 6 capsules of 500 mg barberry extract (n=31)</td>
<td>ONS with placebo (HPMC) (n=31)</td>
<td>3 months</td>
<td>FPG, TG, LDL and HDL levels, BMI, SBP, DBP, anthropometry</td>
<td>BW, BMI, and conicity index increased in both groups, but this was significant only in the placebo group. BF (% of BW), LDL, hips circumference, FPG, and SBP were all decreased in the intervention arm.</td>
</tr>
</tbody>
</table>

ARG: L-arginine; BF: body fat; BIS: bioelectrical impedance spectroscopy; BMD: bone mineral density; BMI: body mass index; BW: body weight; DAS28: disease activity score (28 joints); DBP: diastolic blood pressure; DXA: dual x-ray absorptiometry; ESR: erythrocyte sedimentation rate; FFM: fat-free mass; FM: fat mass; FPG: fasting plasma glucose; GLN: L-glutamine; HDL: high-density lipoprotein; HMB: beta-hydroxy-beta-methylbutyrate; HPMC: hydroxypropyl methylcellulose; IGF: insulin-like growth factor; LDL: low-density lipoprotein; LM: lean mass; ONS: oral nutrient supplementation; RA: rheumatoid arthritis; RC: rheumatoid cachexia; RCT: randomized controlled trial; SBP: systolic blood pressure; TBP: total body protein; TG: triglycerides.